247 related articles for article (PubMed ID: 36696206)
1. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura.
Völker LA; Kaufeld J; Balduin G; Merkel L; Kühne L; Eichenauer DA; Osterholt T; Hägele H; Kann M; Grundmann F; Kolbrink B; Schulte K; Gäckler A; Kribben A; Boss K; Potthoff SA; Rump LC; Schmidt T; Mühlfeld AS; Schulmann K; Hermann M; Gaedeke J; Sauerland K; Bramstedt J; Hinkel UP; Miesbach W; Bauer F; Westhoff TH; Bruck H; Buxhofer-Ausch V; Müller TJ; Wendt R; Harth A; Schreiber A; Seelow E; Tölle M; Gohlisch C; Bieringer M; Geuther G; Jabs WJ; Fischereder M; von Bergwelt-Baildon A; Schönermarck U; Knoebl P; Menne J; Brinkkoetter PT;
J Thromb Haemost; 2023 Mar; 21(3):559-572. PubMed ID: 36696206
[TBL] [Abstract][Full Text] [Related]
2. Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment.
le Besnerais M; Veyradier A; Benhamou Y; Coppo P
Expert Opin Biol Ther; 2019 Nov; 19(11):1127-1134. PubMed ID: 31359806
[No Abstract] [Full Text] [Related]
3. Should we consider caplacizumab as routine treatment for acute thrombotic thrombocytopenic purpura? An expert perspective on the pros and cons.
Seguí IG; Mingot Castellano ME; Izquierdo CP; de la Rubia J
Expert Rev Hematol; 2024; 17(1-3):9-25. PubMed ID: 38353182
[TBL] [Abstract][Full Text] [Related]
4. Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura.
Kühne L; Kaufeld J; Völker LA; Wendt R; Schönermarck U; Hägele H; Osterholt T; Eichenauer DA; Bieringer M; von Bergwelt-Baildon A; Fischereder M; Buxhofer-Ausch V; Menne J; Brinkkoetter PT; Knöbl P
J Thromb Haemost; 2022 Apr; 20(4):951-960. PubMed ID: 35000278
[TBL] [Abstract][Full Text] [Related]
5. Management of immune thrombotic thrombocytopenic purpura with caplacizumab: a Canadian, single-centre, real-world experience.
Tse B; Buchholz M; Pavenski K
Platelets; 2023 Dec; 34(1):2157807. PubMed ID: 36636834
[TBL] [Abstract][Full Text] [Related]
6. ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy.
Mingot-Castellano ME; García-Candel F; Martínez-Nieto J; García-Arroba J; de la Rubia-Comos J; Gómez-Seguí I; Paciello-Coronel ML; Valcárcel-Ferreiras D; Jiménez M; Cid J; Lozano M; García-Gala JM; Angós-Vazquez S; Vara-Pampliega M; Guerra-Domínguez L; Ávila-Idrobo LF; Oliva-Hernandez A; Zalba-Marcos S; Tallón-Ruiz I; Ortega-Sánchez S; Goterris-Viciedo R; Moreno-Jiménez G; Domínguez-Acosta L; Araiz-Ramírez M; Hernández-Mateos L; Flores-Ballesteros E; Del Río-Garma J; Pascual-Izquierdo C
Blood; 2024 May; 143(18):1807-1815. PubMed ID: 38237147
[TBL] [Abstract][Full Text] [Related]
7. Should all patients with immune-mediated thrombotic thrombocytopenic purpura receive caplacizumab?
Picod A; Veyradier A; Coppo P
J Thromb Haemost; 2021 Jan; 19(1):58-67. PubMed ID: 33236389
[TBL] [Abstract][Full Text] [Related]
8. Outcomes and Costs in Patients with Immune Thrombotic Thrombocytopenic Purpura Receiving Front-Line Versus Delayed Caplacizumab: A US Hospital Database Study.
Arnaud A; Schilsky S; Lucia J; Maia M; Laredo F; Marques AP; Okada H; Roberts AW
Clin Appl Thromb Hemost; 2024; 30():10760296241241525. PubMed ID: 38523315
[TBL] [Abstract][Full Text] [Related]
9. Von Willebrand factor assays in patients with acquired immune thrombotic thrombocytopenia purpura treated with caplacizumab.
Bowyer A; Brown P; Hopkins B; Scully M; Shepherd F; Lowe A; Mensah P; Maclean R; Kitchen S; van Veen JJ
Br J Haematol; 2022 May; 197(3):349-358. PubMed ID: 35262910
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study.
Miyakawa Y; Imada K; Ichikawa S; Uchiyama H; Ueda Y; Yonezawa A; Fujitani S; Ogawa Y; Matsushita T; Asakura H; Nishio K; Suzuki K; Hashimoto Y; Murakami H; Tahara S; Tanaka T; Matsumoto M
Int J Hematol; 2023 Mar; 117(3):366-377. PubMed ID: 36427162
[TBL] [Abstract][Full Text] [Related]
11. Caplacizumab to treat immune-mediated thrombotic thrombocytopenic purpura.
Poullin P; Bornet C; Veyradier A; Coppo P
Drugs Today (Barc); 2019 Jun; 55(6):367-376. PubMed ID: 31250841
[TBL] [Abstract][Full Text] [Related]
12. Real-world experience with caplacizumab in the management of acute TTP.
Dutt T; Shaw RJ; Stubbs M; Yong J; Bailiff B; Cranfield T; Crowley MP; Desborough M; Eyre TA; Gooding R; Grainger J; Hanley J; Haughton J; Hermans J; Hill Q; Humphrey L; Lowe G; Lyall H; Mohsin M; Nicolson PLR; Priddee N; Rampotas A; Rayment R; Rhodes S; Taylor A; Thomas W; Tomkins O; Van Veen JJ; Lane S; Toh CH; Scully M
Blood; 2021 Apr; 137(13):1731-1740. PubMed ID: 33150355
[TBL] [Abstract][Full Text] [Related]
13. Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura.
Izquierdo CP; Mingot-Castellano ME; Fuentes AEK; García-Arroba Peinado J; Cid J; Jimenez MM; Valcarcel D; Gómez-Seguí I; de la Rubia J; Martin P; Goterris R; Hernández L; Tallón I; Varea S; Fernández M; García-Muñoz N; Vara M; Zarzoso MF; García-Candel F; Paciello ML; García-García I; Zalba S; Campuzano V; Gala JM; Estévez JV; Jiménez GM; López Lorenzo JL; Arias EG; Freiría C; Solé M; Ávila Idrovo LF; Hernández Castellet JC; Cruz N; Lavilla E; Pérez-Montaña A; Atucha JA; Moreno Beltrán ME; Moreno Macías JR; Salinas R; Del Rio-Garma J
Blood Adv; 2022 Dec; 6(24):6219-6227. PubMed ID: 35930694
[TBL] [Abstract][Full Text] [Related]
14. Autoantibodies enhance ADAMTS-13 clearance in patients with immune thrombotic thrombocytopenic purpura.
Underwood MI; Alwan F; Thomas MR; Scully MA; Crawley JTB
J Thromb Haemost; 2023 Jun; 21(6):1544-1552. PubMed ID: 36813118
[TBL] [Abstract][Full Text] [Related]
15. Persistent ADAMTS13 inhibitor delays recovery of ADAMTS13 activity in caplacizumab-treated Japanese patients with iTTP.
Saito K; Sakai K; Kubo M; Azumi H; Hamamura A; Ochi S; Amagase H; Kunieda H; Ogawa Y; Yagi H; Matsumoto M
Blood Adv; 2024 May; 8(9):2151-2159. PubMed ID: 38386976
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 as a Potential Trigger for Immune Thrombotic Thrombocytopenic Purpura and Reason for an Unusual Treatment: A Case Report.
Schwaegermann MK; Hobohm L; Rausch J; Reuter M; Griemert TF; Sivanathan V; Falter T; Sprinzl MF; Lackner KJ; Galle PR; Konstantinides S; Theobald M; von Auer C
Hamostaseologie; 2023 Jun; 43(3):215-218. PubMed ID: 34327693
[TBL] [Abstract][Full Text] [Related]
17. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.
Peyvandi F; Scully M; Kremer Hovinga JA; Knöbl P; Cataland S; De Beuf K; Callewaert F; De Winter H; Zeldin RK
J Thromb Haemost; 2017 Jul; 15(7):1448-1452. PubMed ID: 28445600
[TBL] [Abstract][Full Text] [Related]
18. Caplacizumab: A game changer also in pregnancy-associated immune-mediated thrombotic thrombocytopenic purpura?
Coppo P; Joly BS;
Br J Haematol; 2023 Aug; 202(4):725-727. PubMed ID: 37291806
[TBL] [Abstract][Full Text] [Related]
19. Delayed normalization of ADAMTS13 activity in acute thrombotic thrombocytopenic purpura in the caplacizumab era.
Prasannan N; Thomas M; Stubbs M; Westwood JP; de Groot R; Singh D; Scully M
Blood; 2023 May; 141(18):2206-2213. PubMed ID: 36720103
[TBL] [Abstract][Full Text] [Related]
20. Taking Empiricism out of Immune Thrombotic Thrombocytopenic Purpura: Current and Future Treatment Strategies.
Mazepa MA; Park YA; Raval JS
Transfus Med Rev; 2019 Oct; 33(4):248-255. PubMed ID: 31645275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
